Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

0 avg rating
( 0 ratings by Goodreads )
 
9780123948106: Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
View all copies of this ISBN edition:
 
 

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics.

  • Provides in-depth coverage of the process of nonclinical safety assessment and comprehensive reviews of each type of biopharmaceutical
  • Contains the most pertinent international regulatory guidance documents for nonclinical evaluation
  • Covers early de-risking strategies and designs of safety assessment programs for novel biopharmaceuticals and vaccines, as well as follow-on biologics or "biosimilars"
  • A multi-authored book with chapters written by qualified experts in their respective fields

"synopsis" may belong to another edition of this title.

Review:

"...brings nonclinical testing of biological and follow-on biological drugs, vaccines plus cell and gene therapy drugs right up to date. It is written in a very readable, yet highly scientific manner and most of the relevant publications...on the topic are referenced...Overall, a ‘must read’ book for all in the nonclinical field of developing biological drugs."--btsNews, June 2014 "Researchers in pharmaceuticals, toxicology, and other biological sciences summarize the current status of developing medicines from biological material, pointing out where the process is different from developing small-molecule medicines and where it is the same. The topics include regulatory guidelines and their application in the non-clinical evaluation of biological medicines, early de-risking strategy for novel biotherapeutics..."--Reference & Research Book News, December 2013

"About this title" may belong to another edition of this title.

Buy New View Book
List Price: US$ 174.95
US$ 145.22

Convert Currency

Shipping: FREE
From United Kingdom to U.S.A.

Destination, Rates & Speeds

Add to Basket

Top Search Results from the AbeBooks Marketplace

1.

Published by Elsevier Science Publishing Co Inc, United States (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Hardcover Quantity Available: 1
Seller:
Book Depository International
(London, United Kingdom)
Rating
[?]

Book Description Elsevier Science Publishing Co Inc, United States, 2013. Hardback. Condition: New. Language: English . Brand New Book. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics. Seller Inventory # LIB9780123948106

More information about this seller | Contact this seller

Buy New
US$ 145.22
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

2.

Published by Academic Press (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Hardcover Quantity Available: 2
Seller:
Murray Media
(North Miami Beach, FL, U.S.A.)
Rating
[?]

Book Description Academic Press, 2013. Hardcover. Condition: New. Never used!. Seller Inventory # P11012394810X

More information about this seller | Contact this seller

Buy New
US$ 145.23
Convert Currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, Rates & Speeds

3.

Plitnick, Lisa
ISBN 10: 012394810X ISBN 13: 9780123948106
New Quantity Available: > 20
Seller:
Paperbackshop-US
(Wood Dale, IL, U.S.A.)
Rating
[?]

Book Description 2013. HRD. Condition: New. New Book. Shipped from US within 10 to 14 business days. Established seller since 2000. Seller Inventory # TE-9780123948106

More information about this seller | Contact this seller

Buy New
US$ 159.90
Convert Currency

Add to Basket

Shipping: US$ 3.99
Within U.S.A.
Destination, Rates & Speeds

4.

Published by Academic Press (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Hardcover Quantity Available: 1
Seller:
Rating
[?]

Book Description Academic Press, 2013. Condition: New. Seller Inventory # L9780123948106

More information about this seller | Contact this seller

Buy New
US$ 163.70
Convert Currency

Add to Basket

Shipping: US$ 3.50
From Germany to U.S.A.
Destination, Rates & Speeds

5.

Published by Elsevier Science Publishing Co Inc, United States (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Hardcover Quantity Available: 1
Seller:
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Elsevier Science Publishing Co Inc, United States, 2013. Hardback. Condition: New. Language: English . Brand New Book. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics. Seller Inventory # LIB9780123948106

More information about this seller | Contact this seller

Buy New
US$ 170.17
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

6.

Published by Elsevier Science Publishing Co Inc, United States (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Hardcover Quantity Available: 10
Seller:
Book Depository hard to find
(London, United Kingdom)
Rating
[?]

Book Description Elsevier Science Publishing Co Inc, United States, 2013. Hardback. Condition: New. Language: English . This book usually ship within 10-15 business days and we will endeavor to dispatch orders quicker than this where possible. Brand New Book. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics. Seller Inventory # EOD9780123948106

More information about this seller | Contact this seller

Buy New
US$ 170.17
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

7.

Lisa Plitnick
Published by Oxford Elsevier LTD Sep 2013 (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Quantity Available: 1
Seller:
Rating
[?]

Book Description Oxford Elsevier LTD Sep 2013, 2013. Buch. Condition: Neu. Neuware - Nonclinical Development of Novel Biologics, Biosimilars and Specialty Biologics is a timely and comprehensive look at the process of nonclinical safety assessment of different types of biopharmaceuticals or biologics. Biologic drugs are a growing and crucial part of the overall pharmaceutical market, largely and generally because they are slightly cheaper to produce, provide higher profit margins and have a higher approval rate than conventional drugs. This reference includes the latest international guidance documents on nonclinical evaluation and a comprehensive review of vaccines, novel biopharmaceuticals, biosimilars and other biologics. By incorporating early de-risking strategies and principles of study design for each type of biopharmaceutical and comparing each to small molecule drugs, this multi-authored book is a valuable resource for all those involved in biologics development. 416 pp. Englisch. Seller Inventory # 9780123948106

More information about this seller | Contact this seller

Buy New
US$ 161.60
Convert Currency

Add to Basket

Shipping: US$ 14.05
From Germany to U.S.A.
Destination, Rates & Speeds

8.

Lisa Plitnick
Published by Oxford Elsevier LTD Sep 2013 (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Quantity Available: 1
Seller:
BuchWeltWeit Inh. Ludwig Meier e.K.
(Bergisch Gladbach, Germany)
Rating
[?]

Book Description Oxford Elsevier LTD Sep 2013, 2013. Buch. Condition: Neu. Neuware - Nonclinical Development of Novel Biologics, Biosimilars and Specialty Biologics is a timely and comprehensive look at the process of nonclinical safety assessment of different types of biopharmaceuticals or biologics. Biologic drugs are a growing and crucial part of the overall pharmaceutical market, largely and generally because they are slightly cheaper to produce, provide higher profit margins and have a higher approval rate than conventional drugs. This reference includes the latest international guidance documents on nonclinical evaluation and a comprehensive review of vaccines, novel biopharmaceuticals, biosimilars and other biologics. By incorporating early de-risking strategies and principles of study design for each type of biopharmaceutical and comparing each to small molecule drugs, this multi-authored book is a valuable resource for all those involved in biologics development. 416 pp. Englisch. Seller Inventory # 9780123948106

More information about this seller | Contact this seller

Buy New
US$ 161.60
Convert Currency

Add to Basket

Shipping: US$ 20.06
From Germany to U.S.A.
Destination, Rates & Speeds

9.

Lisa Plitnick
Published by Oxford Elsevier LTD Sep 2013 (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Quantity Available: 1
Seller:
Rheinberg-Buch
(Bergisch Gladbach, Germany)
Rating
[?]

Book Description Oxford Elsevier LTD Sep 2013, 2013. Buch. Condition: Neu. Neuware - Nonclinical Development of Novel Biologics, Biosimilars and Specialty Biologics is a timely and comprehensive look at the process of nonclinical safety assessment of different types of biopharmaceuticals or biologics. Biologic drugs are a growing and crucial part of the overall pharmaceutical market, largely and generally because they are slightly cheaper to produce, provide higher profit margins and have a higher approval rate than conventional drugs. This reference includes the latest international guidance documents on nonclinical evaluation and a comprehensive review of vaccines, novel biopharmaceuticals, biosimilars and other biologics. By incorporating early de-risking strategies and principles of study design for each type of biopharmaceutical and comparing each to small molecule drugs, this multi-authored book is a valuable resource for all those involved in biologics development. 416 pp. Englisch. Seller Inventory # 9780123948106

More information about this seller | Contact this seller

Buy New
US$ 161.60
Convert Currency

Add to Basket

Shipping: US$ 20.06
From Germany to U.S.A.
Destination, Rates & Speeds

10.

Published by Academic Press (2013)
ISBN 10: 012394810X ISBN 13: 9780123948106
New Hardcover First Edition Quantity Available: 1
Seller:
Irish Booksellers
(Portland, ME, U.S.A.)
Rating
[?]

Book Description Academic Press, 2013. Condition: New. book. Seller Inventory # M012394810X

More information about this seller | Contact this seller

Buy New
US$ 193.72
Convert Currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, Rates & Speeds

There are more copies of this book

View all search results for this book